MMP12, lung function, and COPD in high-risk populations.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 58 citations in OpenAlex.

1. Hydroxamate-Based Selective Macrophage Elastase (MMP-12) Inhibitors and Radiotracers for Molecular Imaging.Journal of medicinal chemistry · 2020
   Article
2. Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease.Journal of medicinal chemistry · 2020
   Article
3. Novel Matrix Metalloproteinase 12 Selective Radiotracers for Vascular Molecular Imaging.Journal of medicinal chemistry · 2019
   Article
4. HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.ACS medicinal chemistry letters · 2018
   Article
5. Relationships of COX2 and MMP12 genetic polymorphisms with chronic obstructive pulmonary disease risk: a meta-analysis.Molecular biology reports · 2014
   Article

Corrections and comments

• Comment on
  MMP12, lung function, and COPD in high-risk populations.2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as